Drug
Vatalanib clinical trials
Also written PTK787 and ZK 222584.
- studies test it
- 32
- open now
- 0
- in phase 3
- 2
- first study started
- 2002
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
31 studies that test it; most in 2005 (12)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 6 |
| 2004 | 6 |
| 2005 | 12 |
| 2006 | 5 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 21
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 26
Novartis (3) · Dana-Farber Cancer Institute (3) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (2) · Washington University School of Medicine (2) · Northwestern University (1) · Daniel George, MD (1)
Often tested with
Tested in the same studies.
Everolimus (2) · Docetaxel (2) · Paclitaxel (2) · Temozolomide (2) · Pemetrexed (1) · Hydroxyurea (1) · Imatinib (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses vatalanib is read from its arms, and is right about nine times in ten.
Testing it · 32
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedPhase 1Mayo ClinicNCT00655655Written as vatalanib
- Trial of PTK787/ZK 222584 Plus PaclitaxelTerminatedPhase 1Dana-Farber Cancer InstituteNCT00358163Written as PTK787/ZK 222584
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.CompletedPhase 3NovartisNCT00056459Written as Vatalanib
- Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid TumorsCompletedPhase 1Mayo ClinicNCT00390000Written as vatalanib
- Vatalanib in Treating Patients With Recurrent or Progressive MeningiomaCompletedPhase 2Northwestern UniversityNCT00348790Written as vatalanib
- Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer PatientsCompletedPhase 1Dana-Farber Cancer InstituteNCT00268918Written as PTK787
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal CancerCompletedPhase 3Novartis PharmaceuticalsNCT00056446Written as Vatalanib
- Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584CompletedPhase 2Novartis PharmaceuticalsNCT00052013Written as PTK787/ZK 222584
- Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic SyndromesCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00072475Written as vatalanib
- PTK787/ZK 222584 in Treating Patients With Unresectable Malignant MesotheliomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00053885Written as PTK787/ZK 222584
- Vatalanib and Everolimus in Treating Patients With Advanced Solid TumorsCompletedPhase 1Daniel George, MDNCT00303732Written as PTK787 (vatalanib)
- PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast CancerTerminatedPhase 1/2Hoosier Cancer Research NetworkNCT00216047Written as PTK787
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant GliomaCompletedPhase 1Duke UniversityNCT00387933Written as vatalanib
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnPhase 2Eastern Cooperative Oncology GroupNCT00227773Written as vatalanib
- Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate CancerCompletedPhase 2University of Michigan Rogel Cancer CenterNCT00134355Written as PTK787
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.CompletedPhase 2BayerNCT00160043Written as PTK787/ ZK 222584
- PTK787 in Refractory or Relapsed Diffuse Large Cell LymphomaTerminatedPhase 2David Rizzieri, MDNCT00511043Written as PTK787
- PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple MyelomaTerminatedPhase 2Washington University School of MedicineNCT00240162Written as PTK787/ZK 222584
- Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic CancerCompletedPhase 1/2George Albert FisherNCT00185588Written as Vatalanib
- Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid TumorsCompletedPhase 1Indiana University School of MedicineNCT00731861Written as Paclitaxel plus PTK787
See all 32 studies that test vatalanib →
Given in every arm · 2 — vatalanib is usual care beside what is tested
Codes
What other systems call vatalanib · ClinicalTrials.gg INT004216
- MeSH (NLM) C404768vatalanibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5DX9U76296VATALANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q7917084vatalanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1868VatalanibOne source FDA
- DrugBank DB04879One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C404768 | vatalanib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5DX9U76296 | VATALANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7917084 | vatalanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1868 | Vatalanib | One source FDA |
| DrugBank | DB04879 | — | One source Wikidata |
Also registered as vatalanib succinate (UNII V5FUB77031).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.